Comparing Patient-Reported Outcomes in Patients Undergoing Lumbar Fusion for Isthmic Spondylolisthesis with Predominant Back Pain versus Predominant Leg Pain Symptoms

Kevin C Jacob, Madhav Patel, Timothy J Hartman, James Nie¹, Omolabake Oyetayo¹, Eileen Zheng, Keith R. Macgregor², Kern Singh²

¹Rush University Medical Center, ²Midwest Orthopaedics At Rush

INTRODUCTION: Prior studies comparing postoperative clinical outcomes in patients undergoing lumbar fusion with predominant back pain versus predominant leg pain symptoms have been limited in the strength of their conclusions. We aim to compare perioperative and postoperative mean patient-reported outcome measures (PROMs) and minimum clinically important difference (MCID) achievement following anterior lumbar interbody fusion (ALIF) and transforaminal lumbar interbody fusion (TLIF) for isthmic spondylolisthesis in patients presenting with predominant back pain symptoms versus predominant leg pain symptoms.

METHODS: A maintained academic single-surgeon database was retrospectively reviewed for lumbar procedures between June 2005 and December 2021. Inclusion criteria was set as primary, elective, single-level anterior or transforaminal lumbar fusion procedures for isthmic spondylolisthesis. Patients undergoing surgery indicated for infectious, malignant, traumatic etiologies, preoperative back pain equivalent to preoperative leg pain, or patients undergoing surgery for degenerative spondylolisthesis, recurrent herniated nucleus pulposus, or degenerative scoliosis were excluded. Additionally, if patients lacked preoperative survey completion or did not complete a 6-month follow-up survey, they were excluded. PROMs were administered at preoperative and 6-week, 12-week, 6-month, 1-year, and 2year postoperative time-points and included Visual Analogue Scale (VAS) for back and leg pain, Oswestry Disability Index (ODI), 12-Item Short Form Physical and Mental Composite Score (SF-12 PCS/MCS), and Patient-Reported Outcome Measurement Information System-Physical Function (PROMIS-PF). Postoperative complications were collected for each cohort as well. Patients were grouped into predominant back pain and predominant leg pain cohorts based on preoperative pain surveys. Predominant back pain cohort consisted of patients with preoperative VAS back > preoperative VAS leg. Predominant leg pain cohort consisted of patients with preoperative VAS leg > preoperative VAS back. Demographic, perioperative characteristics, and mean PROM scores were compared among groups using inferential statistics. Postoperative improvement from preoperative baseline within each cohort was assessed with paired samples t-test. Achievement of Minimum Clinical Important Difference (MCID) was determined by comparing $\Delta PROM$ scores to previously established threshold values. MCID achievement rates were compared between groups with chisquared analysis.

RESULTS:

A total of 143 patients met inclusion criteria with 65 patients in the predominant back pain cohort and 78 patients in the predominant leg pain cohort. Patients in the predominant leg pain cohort demonstrated significantly greater mean postoperative length of stay, estimated blood loss, operative duration, and narcotic consumption on POD0 &1 (p ≤0.028, all). Preoperative mean PROM scores were similar for all PROMs collected except higher VAS leg in the predominant leg pain cohort (p <0.001). Cohorts demonstrated significant mean postoperative differences for the following PROMs at the following postoperative timepoints: VAS leg at 1-year and 2-years, ODI at 2-years, and SF-12 MCS at 1-year with all differences favoring predominant back pain cohort (p ≤0.042, all). Predominant back pain patient cohort demonstrated improvement from respective preoperative baseline to the 2-year timepoint for all postoperative PROMs except ODI at 6-weeks, SF-12 MCS at 6-weeks, 12-weeks, 1-year, and 2-years, SF-12 PCS at 6-weeks, and PROMIS-PF at 6-weeks (p ≤0.033, all). Predominant leg pain patient cohort demonstrated significant improvement from respective preoperative baseline to 2-year timepoint for all postoperative PROMs except VAS back at 2-years, ODI at 6-weeks and 2-years, SF-12 MCS at 1 and 2-years, and PROMIS-PF and SF-12 PCS at 6-weeks (p ≤0.048, all). Both cohorts achieved overall MCID greater than 50% in VAS back, VAS leg, ODI, SF-12 PCS, and PROMIS-PF. Significant differences were noted between cohorts for rate of achievement of MCID for the following PROMs: VAS back at 2-years and VAS leg at 6-weeks, 12-weeks, 6-months, and overall (p ≤0.036, all).

DISCUSSION AND CONCLUSION: Results from our study suggest that patients undergoing lumbar fusion at L4-L5 and L5-S1 for isthmic spondylolisthesis with predominant back pain symptoms may demonstrate improved long-term clinical outcomes for reported back pain, leg pain, and disability when compared to patients presenting for surgery with predominant leg pain symptoms. This subset of patients may additionally experience a reduced postoperative length of stay and consume fewer narcotics on day of surgery and POD1.

| | | | Predominant | |
|--------------------------------|---------------------------|---------------------------------|------------------------|----------|
| | Total (n=143) | Predominant Back Pain (n=65) | Leg Pain (n=78) | *p-value |
| Age (mean ±SD) | 50.7 ± 12.8 | 50.4 ± 12.9 | 50.9 ± 12.8 | 0.805 |
| Gender | | | | |
| Female | 43,4% (62) | 41.5% (27) | 44.9% (35) | 0.689 |
| Male | 56.6% (81) | 58.5% (38) | 55.1% (43) | |
| Body Mass Index Category | | | | |
| (BMI) | | | | 0.408 |
| <30 kg/m ² | 54.6% (78) | 50.8% (33) | 57.7% (45) | |
| ≥30 kg/m² | 45,4% (65) | 49.2% (32) | 42.3% (33) | |
| Body Mass Index (Mean ± | | | | |
| SD) | 30.5 ± 6.5 | 30.8 + 6.9 | 302+63 | 0.565 |
| | 30.5 ± 6.5 | 30.8 ± 6.9 | 30.2 ± 6.3 | |
| Ethnicity Caucasian | ***** | 71.9% (46) | At 144 (50) | |
| African-American | 73.2% (104) | | 71.1% (58) | |
| | 9.9% (14) | 7.8% (5) | 13.2% (9) | |
| Hispanic | 10.6% (15) | 9.4% (6) | 8.6% (9) | 0.332 |
| Asian | 3.5% (5) | 6.3% (4) | 2.2% (1) | 0.332 |
| | 2.8% (4) | 4.7% (3) | 4.9% (1) | |
| Smoking Status Non-Smoker | | 83.1% (54) | 83.3% (65) | 0.967 |
| Non-Smoker Smoker | 83.2% (119) 16.8% (24) | 83.1% (54) 16.9% (11) | 16.7% (65) | 0.967 |
| | 16.8% (24) | 16.9% (11) | 16.7% (13) | |
| Diabetes Non-Diabetic | | | | |
| Non-Dissence Disherie | 93.0% (133) 7.0% (10) | 90.8% (59) | 94.9% (74) 5.1% (4) | 0.338 |
| | 7.0% (10) | 9.2% (6) | 5.1% (4) | |
| Hypertensive Status | 67.8% (97) | 69.2% (45) | 66.7% (52) | 0.744 |
| Non-Hypertensive | 32.2% (46) | | 33.3% (26) | 0,744 |
| Hypertensive | 32.2% (46) | 30.8% (20) | 33.3% (26) | |
| ASA Classification | ** *** **** | | | 0.480 |
| <3 >=1 | 83.9% (120) | 81.5% (53) | 85.9% (67) | ₩.480 |
| | 16.1% (23) | 18.5% (12) | 14.1% (11) | |
| Insurance Medicare/Medicaid | | | | |
| | 7.7% (11) | 6.2% (4) | 9.0% (7) | |
| Workers' Compensation | 29.4% (42) | 24.6% (16) | 33.3% (26) | 0.362 |
| | | | | |

| American Society of Anosthesiologists | |
|---------------------------------------|--|
| | |
| | |
| | |

| | Total (n=143) | Predominant Back Pain (n=65) | Predominant Leg Pain (n=78) | *p-valu |
|---|------------------|------------------------------------|-----------------------------------|---------|
| Spinal Pathology | | | | |
| Central Stenosis | 88.8% (127) | 92.3% (60) | 85.9% (67) | 0.226 |
| Foraminal Stenosis | 46.2% (66) | 64.6% (42) | 30.8% (24) | < 0.001 |
| Isthmic Spondylolisthesis Fusion Procedure | 100.0% (143) | 100.0% (65) | 100.0% (78) | 0.598 |
| MIS-TLIF (2) | 74.8% (107) | 76.9% (50) | 73.1% (57) | |
| ALIF (3) | 25.2% (36) | 23.1% (15) | 26.9% (21) | |
| Fusion Level | 20020000 | | 2000 | 0.657 |
| L2-L3 | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| L2-L4 | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| L3-L4 | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| L3-L5 | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| L4-L5 | 21,7% (31) | 20.0% (13) | 23.1% (18) | |
| L4-S1 | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| L5-81 | 78.3% (112) | 80.0% (52) | 76.9% (60) | |
| Number of Levels Operated | | | | |
| Single Level (0) | | | | |
| Multiple Levels (1) | | | | |
| Operative Time (mean | | | | 0.028 |
| ±SD; min) | 153.5 ± 47.7 | 143.9 ± 41.2 | 161.4 ± 51.5 | |
| Estimated Blood Loss | | | | 0.004 |
| (mean ±SD; mL) | 95.4 ± 99.0 | 68.1 ± 38.3 | 116.8 ± 123.9 | |
| Length of Stay (mean ±SD; | | | | < 0.001 |
| hours) | 46.5 ± 40.7 | 33.0 ± 20.2 | 57.0 ± 48.9 | |
| Post-operative Day of | | | | |
| Discharge (POD) | | | | |
| POD0 | 9.8% (13) | 17.2% (10) | 4.0% (3) | 0.001 |
| POD1 | 42.1% (56) | 56.9% (33) | 30.7% (23) | |
| POD2 | 23.3% (31) | 13.8% (8) | 30.7% (23) | |
| POD3 | 18.8% (25) | 12.1% (7) | 24.0% (18) | |
| POD4 | 3.8% (5) | 0.0% (0) | 6.7% (5) | |
| Postoperative VAS Pain | | | | |
| Score | | | | |
| POD0 | 5.3 ± 1.7 | 5.2 ± 1.9 | 5.4 ± 1.6 | 0.463 |
| POD1 | 4.8 ± 1.9 | 5.0 ± 1.6 | 4.7 ± 2.0 | 0.491 |
| Postoperative Narcotic | | | | |
| Consumption (OME) | | | | |
| POD0 | 78.6 ± 64.9 | 56.3 ± 30.4 | 97.2 ± 78.9 | < 0.001 |
| POD1 | 63.4 ± 78.6 | 44.7 ± 34.9 esterocrative Day | 79.0 ± 99.2 | 0.009 |

| complaint. |
|---|
| *p-value calculated using Student's t-test for continuous variables and chi-square for categorical variable |
| Raldface indicates statistical significance |

| | Predominant Back Pain Mean #SD | Predominant Back Pain Post-operative PROM Improvement | Predominant Leg Pain Mean #SD | Post-open PROM Improvem |
|--------------|--------------------------------------|---|----------------------------------|-------------------------------|
| VAS Back | | | | |
| Preoperative | 6.9 ± 1.9 | | 62+26 | |
| 6-weeks | 4.5 ± 2.5 | <0.001 | 3.9 ± 2.4 | < 0.001 |
| 12-weeks | 4.1 ± 2.6 | < 0.001 | 3.3 ± 2.3 | < 0.001 |
| 6-months | 3.6 ± 2.4 | < 0.001 | 3.4 ± 2.9 | < 0.001 |
| 1-year | 2.5 ± 2.3 | < 0.001 | 3.1 + 2.9 | 0.011 |
| 2-year | 2.4 ± 2.1 | <0.001 | 5.0 ± 3.5 | 0.125 |
| VAS Leg | | | | |
| Preoperative | 4.2 ± 2.7 | | 6.6 ± 2.3 | |
| 6-weeks | 3.2 ± 2.9 | 0.026 | 2.9 ± 2.7 | <0.001 |

| | | | | Predeminant | *p-value | | |
|---------------------|----------------------------|------------------------------------|----------------------------------|--|----------------|---------------------|----------|
| | Predominant | Predominant Back Pain | | Leg Pain Post-operative | *p-vatue | | dominant |
| | Back Pain Mean (SD) | Post-operative PROM Improvement | Predominant Leg Pain Mean #SD | PROM Improvement | | VAS Back 6-weeks | 45 |
| VAS Buck | 31001-00 | | 1441 (1164) - 040 | and the state of t | | | |
| Preoperative | 6.9 ± 1.9 | | 6.2 ± 2.6 | | 0.079 | 12-weeks | 54 |
| 6-weeks | 4.5 ± 2.5 | <0.001 | 3.9 ± 2.4 | <0.001 | 0.144 | 6-months | 64 |
| 12-weeks | 4.1 ± 2.6 | < 0.001 | 3.3 ± 2.3 | < 0.001 | 0.098 | 1-year | 75 |
| 6-months | 3.6 ± 2.4 | <0.001 | 3.4 ± 2.9 | < 0.001 | 0.684 | 2-year | 80 |
| 1-year | 2.5 ± 2.3 2.4 ± 2.1 | <0.001 | 3.1 ± 2.9 5.0 ± 3.5 | 0.011 | 0.373 | Overall | 78.3 |
| 2-year VAS Lee | 24 ± 2.1 | <0.001 | 3.9 ± 3.5 | 9.125 | 0.023 | | /8.3 |
| Properative | 4.2 ± 2.7 | | 6.6 ± 2.3 | | <0.001 | VAS Leg | |
| 6-weeks | 3.2 ± 2.9 | 0.026 | 2.9 ± 2.7 | <0.001 | 9.487 | 6-weeks | 32 |
| 12-weeks | 3.0 ± 2.8 | 0.022 | 23 ± 2.4 | -0.001 | 0.133 | 12-weeks | 24 |
| 6-months | 2.3 ± 2.8 | < 0.001 | 2.3 ± 2.6 | <0.001 | 0.830 | 6-months | 37 |
| 1-year | 1.1 ± 1.9 | < 0.001 | 2.7 ± 3.1 | < 0.001 | 0.042 | | 61 |
| 2-year | 1.6 ± 2.0 | <0.001 | 3.4 ± 4.0 | 0.008 | 0.022 | 1-year | |
| ODI Preoperative | 19.8 ± 14.8 | | 40.6 ± 18.5 | | 0.812 | 2-year | 66 |
| 6-weeks | 34.5 ± 16.7 | 0.116 | 40.6 ± 18.5 34.9 ± 19.7 | 0.054 | 0.916 | Overall | 49.2 |
| 12 weeks | 27.0 + 17.5 | <0.001 | 24.5 ± 18.3 | <0.001 | 0.688 | ODI | |
| 6-months | 25.2 ± 19.8 | <0.001 | 23.0 ± 24.3 | <0.001 | 9.653 | 6-weeks | 24 |
| 1-year | 16.1 ± 18.8 | <0.001 | 25.3 ± 25.4 | 0.002 | 0.065 | 12-weeks | 41 |
| 2-year | 13.5 ± 13.3 | < 0.001 | 28.2 ± 29.5 | 0.186 | 0.036 | | |
| SF-12 MCS | | | | | | 6-months | 53 |
| Preoperative | 50.3 ± 11.1 | 0.083 | 47,0 ± 11,6 | | 0,177 | 1-year | 70 |
| 6-weeks 12-weeks | 52.0 ± 12.0 54.2 ± 10.4 | 0.083 | 53.4 ± 10.1 55.7 ± 11.9 | 0.048 | 0.526 0.510 | 2-year | 75 |
| 6-months | 54.3 ± 11.3 | 0.033 | 55.4 ± 7.9 | 0.020 | 0.760 | Overall | 59.4 |
| 1-year | 54.7 ± 7.8 | 0.054 | 49.4 ± 10.2 | 0.209 | 0.039 | SF-12 MCS | |
| 2-year | 546+88 | 0.996 | 51.3 ± 8.1 | 0.055 | 0.303 | 6-weeks | 22 |
| SF-12 PCS | | | | | | | |
| Prosperative | 31.7 ± 9.5 | | 31.5 ± 9.0 | | 0.891 | 12-weeks | 11 |
| 6-weeks | 32.1 = 8.6 | 0.606 | 32.4 ± 7.9 | 0.797 | 0.940 | 6-months | 28 |
| 12-weeks | 35.5 ± 8.7 | <0.001 | 37.9 ± 9.1 | 0.040 | 0.273 | 1-year | 25 |
| 6-months | 37.6 ± 9.3 45.4 ± 9.7 | <0.001 | 40.0 ± 10.7 40.0 ± 12.3 | 0.007 | 0.099 | 2-year | 5 |
| 1-year 2-year | 43.4 ± 9.7 | <0.001 0.002 | 40.0 ± 12.3 39.3 ± 16.0 | <0.001 0.011 | 0.183 | Overall | 30.9 |
| PROMIS-PF | 41.1 = 11.2 | 0.992 | 39.3 ± 16.0 | 0.011 | 4.659 | | 30.9 |
| Properative | 37.1 ± 5.6 | | 35.9 ± 5.7 | | 0.420 | SF-12 PCS | |
| 6-weeks | 37.9 = 6.1 | 0.907 | 37.4 ± 7.2 | 0.458 | 0.601 | 6-weeks | 48 |
| 12-weeks | 40.6 ± 6.5 | 0.026 | 42.4 ± 6.7 | 0.011 | 0.322 | 12-weeks | 63 |
| 6-months | 43.3 ± 5.7 | < 0.001 | 45.6 ± 10.9 | 0.002 | 0.381 | 6-months | 68 |
| 1-year | 48.2 ± 8.6 | -0.001 | 46.7 ± 11.4 | -0.001 | 0.304 | | |

| | | Predominant Leg Pain | *p-value |
|---------------------|-----------------------|----------------------|----------|
| VAS Back | Predominant Back Pain | | |
| VAS Back 6-weeks | | | |
| | 45.8% | 53.3% | 0.417 |
| 12-weeks | 54.2% | 51.5% | 0.775 |
| 6-months | 64.0% | 50.8% | 0.156 |
| 1-year | 75.0% | 50.0% | 0.086 |
| 2-year | 80.0% | 27.8% | 0.008 |
| Overall | 78.3% (47) | 66.7% (52) | 0.131 |
| VAS Leg | 1007 0000 | | |
| 6-weeks | 32.7% | 56.7% | 0.036 |
| 12-weeks | 24.5% | 62.1% | 0.001 |
| 6-months | 37.3% | 65.4% | 0.019 |
| 1-year | 61.5% | 60.0% | 0.916 |
| 2-year | 66.7% | 66.7% | 1.000 |
| Overall | 49.2% (30) | 79.4% (27) | 0.004 |
| ODI | | | |
| 6-weeks | 24.5% | 18.9% | 0.538 |
| 12-weeks | 41.7% | 39.4% | 0.838 |
| 6-months | 53.6% | 56.7% | 0.783 |
| 1-year | 70.4% | 60.0% | 0.458 |
| 2-year | 75.0% | 42.9% | 0.098 |
| Overall | 59.4% (38) | 60.0% (24) | 0.950 |
| SF-12 MCS | | | |
| 6-weeks | 22.7% | 18.2% | 0.670 |
| 12-weeks | 11.9% | 26.3% | 0.159 |
| 6-months | 28.6% | 21.1% | 0.547 |
| 1-year | 25.9% | 35.3% | 0.507 |
| 2-year | 5.3% | 28.6% | 0.065 |
| Overall | 30.9% (17) | 33.3% (10) | 0.819 |
| SF-12 PCS | | | |
| 6-weeks | 48,8% | 36.4% | 0.338 |
| 12-weeks | 63.4% | 52.6% | 0.428 |
| 6-months | 68.6% | 68.4% | 0.991 |
| 1-year | 81.5% | 82.4% | 0.942 |
| 2-year | 73.7% | \$0.0% | 0.162 |
| Overall | 79.6% (43) | 83.3% (25) | 0.679 |
| PROMIS-PF | | | 3.073 |
| 6-weeks | 29.0% | 36.8% | 0.566 |
| 12-weeks | 48.0% | 46.2% | 0.914 |
| | | | 3.914 |
| 6-months | 65.4% | 73.3% | 0.598 |
| 1-year | 81.0% | 61.5% | 0.212 |
| 2-year | 75.0% | 60.0% | 0.452 |
| Overall | 81.6% (31) | 81.8% (18) | 0.982 |